DeutschNewstral
Article
Bbarrons.com on 2022-05-03 13:26
Biogen to Eliminate Alzheimer's Drug Infrastructure, Search for New CEO1 min read
Related news
- BBiogen Searches for New CEO in Wake of Struggles With Alzheimer's Drug 4 min readbarrons.com
- BBiogen, Eisai's Alzheimer's Data Confirm Benefit, But Questions Loom2 min readbarrons.com
- BBiogen Stock Tumbles After EU Regulator Has Doubts on Controversial Alzheimer's Therapy1 min readbarrons.com
- MBiogen and Eisai make plans to take another Alzheimer's drug to the FDA3 min readmarketwatch.com
- BBiogen Lifts Profit Estimates. The Stock Rises.1 min readbarrons.com
- MBeset by challenges with its Alzheimer's disease drug, Biogen pivots3 min readmarketwatch.com
- BBiogen Sells Stake in Biosimilars Venture for $2.3 Billion1 min readbarrons.com
- BBiogen Is Giving Away Its Controversial Alzheimer's Drug: Report 2 min readbarrons.com
- BBiogen in Pole Position After Roche's Alzheimer's Drug Disappoints3 min readbarrons.com
- BBiogen Says EU Regulator Takes 'Negative Opinion' on Its Alzheimer's Drug1 min readbarrons.com
- BBiogen Is Still a Buy Despite Alzheimer's Drug Concerns, Analyst Says2 min readbarrons.com
- BBiogen Stock Can Go 'Decisively Higher' on Sales of Alzheimer's Drug2 min readbarrons.com
- BRoche Sinks as Alzheimer's Drug Disappoints. Biogen is Gaining. 1 min readbarrons.com
- MBiogen stock rockets to 6-year high after Alzheimer's drug gets FDA OK4 minmarketwatch.com
- BA Third Expert Quits FDA Panel Over Approval of Biogen Alzheimer's Drug 2 minbarrons.com
- BBiogen Stock Is Tumbling Because Its Alzheimer's Drug Rollout Isn't Going So Well2 min readbarrons.com
- BBiogen Stock Drops as Results Fall Short. Sales of Alzheimer's Drug Disappoint.3 min readbarrons.com
Biogen Sees Heavy Patient Interest in New Alzheimer’s Drug4 min readwsj.com- BBiogen and Eisai Strengthen Lead in Alzheimer’s Drug Race. The Stocks Are Rising. 2 min readbarrons.com
- BBig News for Biogen Landed Tuesday. The Company Didn't Get a Mention.3 min readbarrons.com